Cancer immunotherapy with humanized CD47 antibodies is developed21 to augment the macrophage-mediated clearance on tumor cells21,22, demonstrating an anti-tumor efficacy in human cancers23 with tolerable toxicities24. This evidence concerns the gene CD47 and neoplasm.